The UK-based pharmaceuticals company joins an investor group that includes Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda.
Astex Pharmaceuticals, a developer of small molecule therapeutics for oncology, has become a strategic investor in the $100m UK-based Dementia Discovery Fund (DDF), which supports the development of novel dementia treatments.
Astex, a UK-based subsidiary of Japan-headquartered drugs manufacturer Otsuka Group, joins an investor group that includes pharmaceutical firms Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda.
The UK government’s Department of Health and medical charity Alzheimer’s Research UK are also limited partners in the fund, which is managed…
